The lethality of the aggressive brain tumor glioblastoma multiforme (GBM) results in part from its strong propensity to invade surrounding normal brain tissue. Although oncogenic drivers such as epidermal growth factor receptor activation and Phosphatase and Tensin homolog inactivation are thought to promote the motility and invasiveness of GBM cells via phosphatidylinostitol 3-kinase activation, other unexplored mechanisms may also contribute to malignancy. Here we demonstrate that several components of the planar cell polarity (PCP) arm of non-canonical Wnt signaling including VANGL1, VANGL2 and FZD7 are transcriptionally upregulated in glioma and correlate with poorer patient outcome. Knockdown of the core PCP pathway component VANGL1 suppresses the motility of GBM cell lines, pointing to an important mechanistic role for this pathway in glioblastoma malignancy. We further observe that restoration of Nrdp1, a RING finger type E3 ubiquitin ligase whose suppression in GBM also correlates with poor prognosis, reduces GBM cell migration and invasiveness by suppressing PCP signaling. Our observations indicate that Nrdp1 physically interacts with the Vangl1 and Vangl2 proteins to mediate the K63-linked polyubiquitination of the Dishevelled, Egl-10 and Pleckstrin (DEP) domain of the Wnt pathway protein Dishevelled (Dvl). Ubiquitination hinders Dvl binding to phosphatidic acid, an interaction necessary for efficient Dvl recruitment to the plasma membrane upon Wnt stimulation of Fzd receptor and for the propagation of downstream signals. We conclude that the PCP pathway contributes significantly to the motility and hence the invasiveness of GBM cells, and that Nrdp1 acts as a negative regulator of PCP signaling by inhibiting Dvl through a novel polyubiquitination mechanism. We propose that the upregulation of core PCP components, together with the loss of the key negative regulator Nrdp1, act coordinately to promote GBM invasiveness and malignancy.
INTRODUCTION
Glioblastoma multiforme (GBM) is the most lethal brain cancer, representing 45% of malignant primary central nervous system tumors. 1 Despite a standard of care involving surgical resection of the primary tumor followed by radiation and chemotherapy, median survival time is about 1 year, and only 5% of patients survive 5 years past diagnosis. 2 Sub-populations of cells within heterogeneous tumors often exhibit the highly invasive properties responsible for surgical evasion and recurrence. These cells, whose migratory ability is unhindered by radiation therapy, invade vital parts of the patient's brain leading to inevitable death. 3, 4 Common molecular drivers of GBM include overexpression or mutation of epidermal growth factor receptor, elevation of platelet-derived growth factor ligands and receptors, and loss of the tumor-suppressor Phosphatase and Tensin Homolog. 5 Downstream signaling through the phosphatidylinostitol 3-kinase/Akt pathway promotes migration, and disruption of phosphatidylinostitol 3-kinase/Akt signaling in GBM cells can partially suppress cellular invasion. 6 However, alterations in other molecular pathways such as Wnt signaling also promote invasive processes, 7 and it is likely that dysregulation of multiple signaling pathways contributes to GBM aggressiveness.
A common theme in tumorigenesis concerns the reactivation of embryonic developmental pathways to promote tumor growth and malignancy. Planar cell polarity (PCP) is a well-characterized pathway in Drosophila development essential for generating epithelial cell polarity in the planar axis orthogonal to the apical-basal axis. Signaling via the tetraspanin-like scaffolds Vangl1 and Vangl2 in mammals comprises a branch of non-canonical Wnt signaling associated with developmental PCP, and dysregulation of this pathway is associated with various disease states. 8, 9 In Vangldependent non-canonical Wnt signaling, the Frizzled (Fzd) receptor is activated by Wnt ligand binding, followed by Dishevelled (Dvl) recruitment to the plasma membrane. These events give rise to downstream activation of c-Jun N-terminal kinase and the small GTPases Rac1 and RhoA, resulting in AP1 transcriptional activation and cytoskeletal rearrangements. 8 Signaling through this pathway can be localized to specific subcellular regions by the presence of Vangl to promote directed cell movements. 9, 10 Although PCP signaling in development is well established, its role in tumor biology is just beginning to emerge. Vangl proteins localize to the leading edge of lamellapodia and to the base and arms of actin protrusions of migrating breast cancer cells, and VANGL1 knockdown in these cells reduces motility. 10, 11 While the mechanism by which Vangl-dependent non-canonical Wnt signaling regulates cell migration remains unknown, mounting evidence suggests that signaling mediated by Vangl proteins is hijacked by tumors to modulate cell invasiveness. Vangl1 and/or Vangl2 dysregulation has been reported in several cancer types, including GBM. 12, 13 Higher Vangl1 transcript and protein is associated with increased tumor grade and reduced survival in glioma patients. Further, Vangl1 overexpression in a murine glioma line increases cell migration and reduces survival in mice with orthotopic xenografts, whereas Vangl1 loss suppresses U251 cell motility and prolongs survival in a similar xenograft model. 12 These observations suggest that Vangl-dependent non-canonical Wnt signaling contributes to GBM progression.
Nrdp1 is a RING finger E3 ubiquitin ligase that mediates the ubiquitination of several protein targets involved in cancer progression, including the inhibitor of apoptosis protein BRUCE 14 and the growth factor receptors ErbB3 and ErbB4. 15 Loss of Nrdp1 has been associated with breast cancer, 16, 17 prostate cancer, 18 colon cancer 19 and recently GBM. In glioma cell lines, reexpression of Nrdp1 has been reported to reduce BRUCE levels and increase apoptosis in response to temozolomide treatment, 20 and may reduce cell migration in a subset of gliomas via ErbB3 suppression. 21 However, although increased signaling through phosphatidylinostitol 3-kinase/Akt is a hallmark of glioma, ErbB3 is not commonly dysregulated in GBM, 22 suggesting that other Nrdp1-mediated pathways regulate migration in brain tumors.
Here we report that VANGL1 and VANGL2 are overexpressed and NRDP1 is suppressed in brain tumors relative to normal brain tissue, and that restoration of Nrdp1 to GBM cell lines reduces cellular motility and invasiveness. We further demonstrate that Nrdp1 interacts with Vangl1 and Vangl2 to mediate the ubiquitination of Dvl proteins, downregulating PCP signaling by suppressing Dvl recruitment to activated Fzd receptor. These observations point to a novel role for Nrdp1 in suppressing Vangldependent non-canonical Wnt signaling, and highlight an unappreciated role for this pathway in regulating the motility of GBM cells.
RESULTS

Nrdp1 inhibits GBM cell invasiveness
Using publicly available microarray data, we observed that NRDP1 transcript is significantly lower in brain tumor samples than nontumor brain samples in the REMBRANDT data set ( Figure 1a and Supplementary Figure S1A) , regardless of molecular subtype (Supplementary Figure S1B) . 23 Moreover, low NRDP1 transcript levels are associated with decreased patient survival ( Figure 1b and Supplementary Figure S1C ), raising the possibility that NRDP1 suppression contributes to disease progression and mortality.
To assess the impact of Nrdp1 protein on GBM biology, we restored its complementary DNA to Phosphatase and Tensin Homolog (PTEN)-mutated GBM cell lines A1207, T98G and U87-MG. We observed that Nrdp1 expression alters cellular morphology, favoring flatter cells with fewer protrusions (Figure 2a) , and suppresses motility, as well as invasiveness in Matrigel-coated Boyden chambers (Figures 2b and c) . Conversely, short hairpin RNA-mediated suppression of the low endogenous levels of NRDP1 in T98G (Supplementary Figures S2A and B) and U87-MG cells (Supplementary Figure S2D Figure S2F) . However, Nrdp1 restoration does not alter the proliferation of GBM lines (Supplementary Figure S2G) , suggesting that Nrdp1 is a specific negative regulator of GBM migration and invasiveness.
To assess the impact of Nrdp1 restoration on GBM invasiveness in brain tissue, we examined the dissemination of highly invasive green fluorescent protein (GFP)-labeled U251 cells into cultured slices of mouse brain. Like the other glioma lines, Nrdp1 restoration to U251 cells (Supplementary Figure S3A) induces a more flattened morphology (Supplementary Figure S3B) and suppresses their migration (Supplementary Figure S3D) , but does not impact their proliferation (Supplementary Figure S3C) . We observed that when seeded on brain slices, U251 cells with restored Nrdp1 disseminated less efficiently than control cells, as determined histologically and by anti-GFP staining (Figures 2d and e) , providing strong evidence that Nrdp1 is a potent negative regulator of brain tumor invasiveness.
Although Nrdp1 is most well characterized as a negative regulator of the ErbB3 and ErbB4 receptor tyrosine kinases, 15 previous studies indicate that neither receptor is significantly dysregulated in GBM. 22 Similarly, levels of epidermal growth factor receptor and phosphorylation of signaling intermediates Akt and Erk are not altered upon Nrdp1 restoration (Supplementary Figure S4A ), consistent with its inability to influence GBM cell proliferation. β-Catenin phosphorylation is also not affected by Nrdp1 (Supplementary Figures S4B and C Figures S4H and I ), suggesting that Nrdp1 may regulate non-canonical Wnt signaling. 8, 24 Nrdp1 interacts with Vangl1 and Vangl2 Wnt signaling is broadly separated into two categories. Canonical Wnt signaling results in stabilized β-catenin, most often regulating proliferation and differentiation. Non-canonical Wnt signaling consists of several interconnected pathways defined by β-catenin independence, and activation of these pathways often results in AP1-dependent transcription through phospho-c-Jun N-terminal kinase and increased cell motility through Rac and/or Rho. 8, 24 Nrdp1 may regulate non-canonical Wnt signaling and GBM migration by interacting with the non-canonical Wnt components Vangl1 and Vangl2, interactions first identified in a published Master's thesis. 25 The Vangl proteins are critical for PCP, and lossof-function Vangl mutants lead to developmental defects in multiple tissues. As Vangl1 and Vangl2 have nearly identical protein structures and biochemical properties, variation in their developmental roles 26 may arise from differential tissue or temporal expression. Still, Vangl proteins have been linked to migration and invasion in several carcinomas 13 and expression of both VANGL1 and VANGL2 is increased in GBM (Figure 3a) . Indeed, aberrant expression of core Vangl-dependent non-canonical Wnt signaling components appears to be a common feature of glialderived brain tumors across molecular subtypes, as transcripts of the Wnt ligand WNT5A and the transmembrane Wnt receptor FZD7 are also elevated compared with non-tumor brain tissue (Supplementary Figures S5A and B) . Dysregulation of this pathway is also associated with decreased patient survival times (Supplementary Figures S5C-F) , underscoring the important role of PCP signaling in promoting dissemination.
We confirmed the interaction of Vangl1 and Vangl2 with Nrdp1 through co-immunoprecipitation assays in HEK293T cells (Supplementary Figures S6A and B) . Importantly, endogenous Vangl2 and Nrdp1 could be co-immunoprecipitated from mouse brain lysates, demonstrating the physiological relevance of this interaction (Supplementary Figure S6C) . Vangl proteins contain an intracellular N-terminal region with multiple phosphorylation sites, 27 four transmembrane domains, and an intracellular C-terminal region with a coiled-coil domain and PDZ-binding motif. 28 To determine the Vangl2 region responsible for interacting with Nrdp1, we used deletion mutants (Supplementary Figure S6D) . Only the Vangl2ΔC mutant fails to precipitate with Nrdp1 (Supplementary Figure S6E) , indicating that Nrdp1 interacts with the Vangl2 C-terminus. The Vangl2ΔCC mutant may have a diminished interaction with Nrdp1, of interest because Nrdp1 itself has a coiled-coil domain and these domains often self-associate. 29 Indeed, Nrdp1 lacking this domain (Nrdp1ΔCC in Supplementary Figure S6F ) does not interact with Vangl2 (Supplementary Figure S6G) , suggesting that the Nrdp1 coiled-coil domain is necessary for the Nrdp1-Vangl2 interaction, whereas the Vangl2 coiled-coil domain supports but is dispensable for the interaction. We have demonstrated that the Nrdp1 coiled-coil domain mediates Nrdp1 oligomerization, 29 and it is possible that Vangl2 interacts with Nrdp1 oligomers or disrupts Nrdp1 oligomerization. Surprisingly, neither augmented ubiquitination of Vangl1 or Vangl2 (Supplementary Figures S7A and B ) nor suppressed Vangl protein levels (Supplementary Figure S7C) is observed with Nrdp1 expression, implying that Vangl1 and Vangl2 could serve as scaffolds for Nrdp1 as they do in previously characterized modes of PCP. 30, 31 Dvl is subject to Nrdp1-mediated ubiquitination Although the precise molecular complexes involved in each branch of non-canonical Wnt signaling are not clearly defined, most branches engage the scaffolding protein family Dvl. 24 As Dvl proteins are regulated by ubiquitination, 32 we tested whether they are substrates for Nrdp1-mediated ubiquitination. Each of the three Dvl family members exhibits increased ubiquitination when co-expressed with Vangl2 and Nrdp1 ( Figure 3b and Supplementary Figure S7D ). Interestingly, Nrdp1-mediated Dvl ubiquitination occurs only in the presence of Vangl2, demonstrating that Nrdp1 alone is insufficient to promote Dvl ubiquitination, (Figure 3c) , and a double point-mutant of the Nrdp1 RING domain (Nrdp1-CHSQ-FLAG) that cannot catalyze transfer of ubiquitin from the E2 to the substrate 33 is unable to promote ubiquitination of Dvl2 (Supplementary Figures S7E and F) , indicating that the ubiquitin ligase activity of Nrdp1 is necessary for Dvl ubiquitination. As Nrdp1 promotes ubiquitination of endogenous Dvl2 in T98G cells (Figure 3d ) but does not alter expression of WNT5A or VANGL1 (Supplementary Figure S8) , Nrdp1-mediated regulation of noncanonical Wnt signaling via Dvl ubiquitination may be responsible for the decreased motility in these cells. However, Nrdp1 does not promote Dvl2 degradation, as its expression in GBM cell lines does not decrease endogenous Dvl2 protein (Supplementary Figure S7G) .
Polyubiquitination consists of ubiquitin monomers chained through any of seven lysines or the N-terminal amino group, most commonly utilizing K48, K63 or K11. 34 To determine the ubiquitin linkage on Dvl2 promoted by Nrdp1, we conducted ubiquitination assays using ubiquitin mutants where K48, K63 or K11 is mutated to arginine, thus preventing polyubiquitination through the mutated lysine. We observed that only the K63R mutant cannot form polyubiquitin chains on Dvl2 (Figure 3e ), indicating that Nrdp1 promotes K63-linked polyubiquitination of Dvl2. This complements our observation that Nrdp1 does not promote endogenous Dvl2 degradation; unlike K48 and K11-linked ubiquitin chains, K63-linked poyubiquitination is not typically a degradation marker, but promotes context-dependent regulation of protein activity and complexes. 34 These observations suggest that Nrdp1-mediated K63-linked polyubiquitination of Dvl proteins alters Dvl function to suppress GBM cell motility.
Nrdp1-mediated ubiquitination prevents Dvl binding to phosphatidic acid (PA) We next explored the mechanism whereby Nrdp1-mediated Dvl ubiquitination impairs PCP signaling. Dvl proteins have three domains: the Dishevelled, Egl-10 and Pleckstrin (DEP) and PDZ domains, required for both canonical and non-canonical Wnt signaling, and the DIX domain, required for canonical Wnt signaling. 24 Using Dvl1 mutants with the lysines in each domain mutated to arginines (Figure 4a ), we determined that the Dvl1-DEP-6KR mutant is resistant to Nrdp1-mediated ubiquitination (Figures 4b and c) , mapping the predominant Nrdp1 polyubiquitination sites to the DEP domain. As the Dvl1-DEP-6KR mutant interacts normally with Vangl2 (Supplementary Figure S9A) , this decreased ubiquitination is likely not the result of impaired Dvl-DEP-6KR folding or function.
The Dvl-DEP domain interacts with PA within the plasma membrane inner leaflet through an electrostatic interaction between negatively charged PA and positively charged lysine and arginine residues on the DEP membrane-binding face. Recruitment to the plasma membrane by these residues is necessary for efficient formation of complexes between Dvl and the Wnt receptor Fzd. 35 Five mutated lysines in the Dvl1-DEP-6KR mutant are on this membrane-binding face (Supplementary Figure S9B) , suggesting that ubiquitination of these residues could reduce the affinity of the DEP domain for PA by steric hindrance. To test this, we overlayed purified Dvl1 onto phospholipid strips to assess alterations in the avidity of Dvl1 for PA upon Nrdp1-mediated ubiquitination ( Figures 4D and E) . Vangl2 increases the amount of Dvl1 bound to PA, consistent with its pro-migratory role. 10, 11 However, in the presence of Vangl2 and Nrdp1, Dvl1 binding to PA is significantly decreased, suggesting that Nrdp1-mediated ubiquitination inhibits Dvl function by preventing its association with the plasma membrane. To confirm that Nrdp1 abrogates the Dvl-PA interaction by promoting DEP ubiquitination, we overlaid Dvl1 wild-type (Dvl1-WT) or Dvl1-DEP-6KR onto lipid strips (Supplementary Figure S9C) . Although Nrdp1 reduces the affinity of Dvl1-WT for PA, the Dvl1-DEP-6KR mutant resists the effects of Nrdp1 and retains PA-binding potential. We conclude that Nrdp1 inhibits signaling through Dvl by mediating the ubiquitination of the DEP domain region necessary for interaction with the plasma membrane.
Nrdp1 promotes Dvl segregation into a Vangl complex A recurring theme in Vangl-dependent non-canonical Wnt signaling is intracellular segregation of protein complexes to limit active signaling to specific subcellular areas to promote directed movement. Non-canonical Wnt ligand binds to Fzd receptors, which drives formation of active Fzd-Dvl complexes at the tips of migratory protrusions, whereas Vangl localizes to the arms of these protrusions. 9, 10 As Fzd and Vangl display mutually exclusive localization yet both interact with Dvl, we hypothesized that they compete for Dvl and that Nrdp1 influences this competition to suppress Dvl activation. In the presence of Wnt5a, increasing amounts of Fzd7 results in decreased amounts of Dvl1 co-immunoprecipitated with Vangl2 (Figure 5a) , consistent with a model where ligand-bound Fzd competes with Vangl2 for available Dvl1. Nrdp1 expression favors Dvl1-Vangl2 complex maintenance, decreasing the ability of Fzd7 to inhibit this interaction (Figures 5a and b) and suppressing the accumulation of active, phosphorylated Dvl1 36 ( Figures 5c and d) , suggesting that polyubiquitinated Dvl cannot form the active Fzd-Dvl complexes necessary for directed migration. Similarly, restoration of Nrdp1 to T98G cells suppresses Wnt5a-induced accumulation of phospho-Dvl2, implying that Nrdp1 interferes with Fzd-induced Dvl signaling in GBM cells (Figures 5e and f) .
To demonstrate that Nrdp1-mediated Vangl-dependent ubiquitination of Dvl is relevant in GBM cell lines, we sought to knockdown Vangl. A1207 and T98G cells do not express VANGL2 (Supplementary Figure S10A) , and VANGL1 expression in these cell lines can be decreased with two independent short hairpin RNAs (Supplementary Figure S10B) . In T98G cells, VANGL1 knockdown significantly decreases Nrdp1-mediated Dvl2 ubiquitination (Figures 6a and b) , again demonstrating that Vangl proteins are a critical link between Nrdp1 and its Dvl substrate. VANGL1 knockdown is sufficient to inhibit migration in A1207 and T98G cells (Figure 6c ), indicating that Vangl-dependent non-canonical Wnt signaling promotes GBM migration, and mirroring results observed in breast cancer cells. 10, 11 However, in the presence of Nrdp1, VANGL1 knockdown has no additional effect on cell migration, implying that Nrdp1 and Vangl1 regulate GBM migration through the same pathway.
DISCUSSION
Collectively, our observations underscore the importance of the PCP pathway in glioma malignancy, and establish Nrdp1 as a central regulator of PCP signaling. Although dysregulation of NRDP1, VANGL1 and WNT5A 12, 20, 37 in GBM has been reported in small sample sizes, our study finds that in large, publicly available microarray data sets the collective dysregulation of Vangl- dependent non-canonical Wnt signaling components NRDP1, VANGL1, VANGL2, WNT5A and FZD7 is a nearly ubiquitous event in GBMs of all molecular subtypes and lower grade astrocytomas and oligodendrogliomas. The correlation of aberrant expression of these components with decreased patient survival is strong evidence that aberrant PCP activation promotes glioma cell invasiveness, a primary cause of relapse in GBM patients.
We hypothesize that Nrdp1 promotes K63-linked polyubiquitination of Dvl to suppress Vangl-dependent non-canonical Wnt signaling ( Figure 7) . Upon pathway activation, Dvl binds to the negatively charged plasma membrane phospholipid PA via positively charged residues (K409, K456, R461, R464, K465, K472 and K482) in the DEP domain; 38 mutation of these lysine residues to glutamate reduces the PA-binding ability of Dvl and Fzddependent membrane recruitment. 35 We demonstrate that Nrdp1-mediated ubiquitination modifies the DEP domain of Dvl and abrogates its ability to bind PA using the Dvl1-DEP-6KR mutant. Although Nrdp1 suppresses the interaction between Dvl1-WT and PA, Dvl1-DEP-6KR largely lacks polyubiquitination and retains PA binding in the presence of Nrdp1. These results imply that the critical Nrdp1-mediated polyubiquitination sites are on this polybasic face of the DEP domain, where ubiquitination disrupts membrane binding by sterically hindering the interaction. The mutated lysine in the Dvl1-DEP-6KR mutant not in the polybasic face, K434, participates in canonical Wnt/β-catenin signaling and likely does not contribute to Nrdp1-mediated negative regulation of Dvl. 39 We also find that Nrdp1 inhibits Dvl phosphorylation and promotes maintenance of Dvl-Vangl complexes in the presence of Fzd and Wnt5a. In this model, Nrdp1 favors the Dvl-Vangl complex by decreasing the affinity of Dvl for PA, which is necessary for formation of the Dvl-Fzd complex and downstream signaling.
Ubiquitination is a common mechanism of Dvl regulation in both arms of Wnt signaling. Multiple E3 ubiquitin ligases promote Dvl turnover through proteasomal degradation, 32 while several E3 ubiquitin ligases in addition to Nrdp1 have been shown to promote K63-linked polyubiquitination of Dvl. The HECT E3 ligase Huwe1 inhibits canonical Wnt signaling by preventing formation of Dvl oligomers via K63-linked polyubiquitination of Dvl, 40 whereas the RING E3 ligase PDZRN3 promotes non-canonical Wnt signaling by K63-linked polyubiquitination of the DIX domain to regulate Dvl3-Fzd4 complex endocytosis. 41 Nrdp1-mediated Dvl ubiquitination inhibits Dvl membrane binding, a mechanism distinct from Huwe1 or PDZRN3, demonstrating the contextdependent versatility of K63-linked polyubiquitination of a single protein.
Nrdp1 has been previously linked to cell polarity through its interaction with the Ser/Thr kinase MARK2 (Par-1b) in breast epithelial cells, where disrupting MARK2-dependent phosphorylation of Nrdp1 prevents proper apical-basal polarity. 42 As Vangldependent non-canonical Wnt signaling is required for PCP establishment in development, Nrdp1 may regulate polarity in two axes. There is precedent for interplay between these polarity pathways; Scribble, a Drosophila PCP effector that interacts with Vang/Vangl in Drosophila and mammalian cells, 11 is a wellcharacterized component of the basolateral complex that maintains apical-basal polarity. 43 This suggests that the two polarity modes may be more closely linked than previously appreciated, and future studies are needed to establish the extent to which Nrdp1 regulates polarity both in development and disease.
Although Nrdp1 levels are decreased in many cancer types, the role and regulation of Nrdp1 seem to vary markedly. In breast cancer, aberrant ErbB3 signaling is associated with loss of Nrdp1 protein despite unchanged mRNA levels. 17 However, NRDP1 transcript is decreased in GBM tumors, implying that different regulatory mechanisms govern NRDP1 expression in these tumors. To date, the only known transcriptional regulator of NRDP1 is the androgen receptor in prostate cancer, 18 which is not known to have a significant role in GBM. Just as signaling through the ErbB3-Akt axis stabilizes Nrdp1 protein in a negative feedback loop, 44 it is possible that non-canonical Wnt signaling regulates NRDP1 transcript. However, VANGL1 knockdown does not change NRDP1 transcript levels in GBM cell lines (Supplementary Figure S10C) , suggesting that a feedback loop between Vangldependent non-canonical Wnt signaling and NRDP1 gene regulation does not exist. The mechanism governing NRDP1 transcript loss in GBM should be the subject of further study, as its restoration may decrease GBM invasiveness.
In summary, this study is the first to demonstrate that Nrdp1 regulates Wnt signaling, and we propose that loss of Nrdp1 in aggressive GBM tumors contributes to aberrant activation of a Vangl-dependent non-canonical Wnt pathway to promote tumor invasion. Our findings contribute significantly to the understanding of Dvl regulation, highlighting another avenue through which non-canonical Wnt signaling is disrupted in tumor biology. Moreover, our findings underscore the role of PCP signaling in GBM motility and invasiveness, suggesting that targeting the Transfection and transduction HEK293T cells were transfected using 4 μg polyethylenimine (Sigma) per μg DNA, and T98G cells were transfected with Lipofectamine 3000 (Life Technologies, Waltham, MA, USA). HA-tagged ubiquitin (#17608), HAtagged K48R and K63R ubiquitin mutants (#17604 and #17606), Wnt5a (#35911), and mouse Fzd7 (#42259) were from Addgene (Cambridge, MA, USA). K11 in HA-tagged ubiquitin was replaced with arginine using site-directed mutagenesis to generate the K11R mutant. Fzd7 was subcloned into pcDNA3.1(+) with a C-terminal HA-tag. Vangl1 and Vangl2 plasmids were from the Harvard PlasmID repository (Boston, MA, USA) (HsCD00339551 and HsCD00294893) and subcloned into pcDNA3.1(+) with N-terminal FLAG and V5 epitope tags, respectively. Nrdp1-CHSQ-FLAG, Nrdp1-ΔCC (FLAG-tag removed by site-directed mutagenesis), and wildtype Nrdp1-V5 and Nrdp1-FLAG were described. 15, 29, 33 Plasmids encoding human Myc-Dvl2 and Myc-Dvl3 were gifts from Dr Hiroaki Miki. 45 Wild-type mouse FLAG-Dvl1, FLAG-Dvl1-DIX-7KR and FLAG-Dvl1-PDZ-3KR were gifts from Dr Madelon Maurice. 46 K409, K434, K458, K465, K472 and K482 in FLAG-Dvl1 were replaced with arginines using site-directed mutagenesis to generate FLAG-Dvl1-DEP-6KR.
The pMXpie-Nrdp1-FLAG, pMXpie-Nrdp1 (FLAG-tag removed by site-directed mutagenesis), pMXpie control, pSuper-shNrdp1-KD1 and -KD4 knockdown plasmids, and pSuper-scramble control have been described. 16, 47 Plasmids were transfected into HEK-293-GPG cells to produce VSVG-pseudotyped retrovirus as described. 16 Stable cell lines were transduced with 12 μg/ml protamine sulfate (MP Biomedicals, Solon, OH, USA), followed by drug selection with 1 μg/ml puromycin (Sigma) for pMXpie or 200 μg/ml neomycin (G418; VWR, Radnor, PA, USA) for pSuper.
Human Nrdp1 short hairpin RNA pLKO.1 (#51, ID:TRCN0000034251; #53, ID:TRCN0000034253) and human Vangl1 short hairpin RNA pLKO.1 (#90, ID: TRCN0000062090; #92, ID: TRCN0000062092) lentiviral constructs were from Open Biosystems (Lafayette, CO, USA), and scramble control pLKO.1 was from Addgene (Billerica, MA, USA) (#1864). VSVG-pseudotyped lentivirus was generated by transfecting HEK293T cells with psPax2 packaging vector. Cells were transduced with 10 μg/ml polybrene (Millipore, Billerica, MA, USA), followed by drug selection with 1 μg/ml puromycin.
Gene expression and outcome analyses
Expression analysis was conducted using the REMBRANDT data set (https:// gdoc.georgetown.edu/gdoc/, access date: 07 June 2016) (X201962_s_at NRDP1, X229997_at VANGL1, X226029_at VANGL2, X213425_at WNT5A and X203706_s_at FZD7). 48 Analysis of tumors of known molecular subtype was carried out using the TCGA subset included in Verhaak et al. 23 P-values were determined by Mann-Whitney-Wilcoxon test and box-plots were created using GraphPad Prism. Kaplan-Meier analysis was conducted using the REMBRANDT data set and P-values were determined by log-rank test using Prism GraphPad (La Jolla, CA, USA).
PCR
Total RNA was isolated using the RNeasy Mini Kit (Qiagen, Hilden Germany) and DNaseI treated (Roche) according to the manufacturer's protocol. The high-capacity complementary DNA reverse transcription kit (Applied Biosystems, Waltham, MA, USA) was used to make complementary DNA, and PCR analysis was performed using the following primer sets: Vangl1 (5′-GGACTCAAGCCACAACGAGTTGTAT-3′) and (5′-ACTACGAGGCTGAA-GTCCAAGC-3′), and Vangl2 (5′-ATGAGCGGGATGACAACTGG-3′ and 5′-ACCTTGAGCGTGAACTGAGG-3′). Quantitative real-time PCR was performed in a Bio-Rad (Hercules, CA, USA) iCycler CFX-96 real-time PCR machine using SsoAdvanced Universal Probes Supermix (Bio-Rad) and TaqMan gene-specific primer/probe sets (Applied Biosystems). Levels for VANGL1 (Hs01572998_m1), WNT5A (Hs00998537_m1) and NRDP1/RNF41 (Hs00195064_m1) were normalized to glyceraldehyde-3-phosphate dehydrogenase (GAPDH, 4352934E) levels for each sample.
Motility and invasion assays
Cells were plated on chambers with 8 μm pore polycarbonate membranes (Corning, Corning, NY, USA) and seeded in Dulbecco's modified Eagle's medium with 0.01% fetal calf serum, migrating overnight toward the lower chamber containing Dulbecco's modified Eagle's medium with 10% fetal calf serum. Migrated cells were fixed and stained with Diff-Quick staining solution (Dade Behring, Deerfield, IL, USA). For cell invasion assays, chambers pre-coated with Matrigel (BD Biosciences) were employed. Cells that migrated or invaded were imaged and counted in five microscopic fields per filter on an Olympus (Center Valley, PA, USA) IX81 microscope with Olympus cellSens Entry software. Results were normalized to proliferation rates and averaged among at least three independent experiments.
Organotypic brain slice invasion assays
Animal studies were conducted according to protocols approved by the IACUC of the University of California, Davis, CA, USA. Fresh brain tissue sections from wild-type FvB mice 12-15 weeks of age were prepared under sterile conditions immediately after sacrifice using a precision brain slicer (Braintree Scientific, Inc., Braintree, MA, USA). High-quality 1 mm coronal tissue slices were cut in half (sagittal plane) in dissection media (minimum essential medium with glutamine, 1% penicillin/streptomycin, 50 μg/ml gentamycin (Thermo, Waltham, MA, USA) and 4.5 mg/ml D-glucose (Sigma)). The matching left and right hemisphere sections were then placed on sterile porous (0.4 μm) membranes in a 12-well Transwell plate (Corning) and co-cultured with 250 000 U251 cells either expressing pMXpie control or pMXpie-Nrdp1-FLAG in brain culture media (50% dissection media, 25% Hanks' balanced salt solution, 25% horse serum, 1% penicillin/streptomycin, 50 μg/ml gentamycin, 1x non-essential amino acids (Thermo)). Media was replaced in both the upper and lower chambers of the transwell plate after 2-3 days. At 5 days, the tissue was gently washed with phosphate-buffered saline (PBS), fixed in 10% neutral buffered formalin, and embedded in 1% agarose for stability during histological processing and paraffin embedding. Representative 5 μm thick sections about 50, 100 and 200 μm deep were processed for both hematoxylin and eosin and anti-GFP (Clontech, Mountain View, CA, USA) IHC.
Co-immunoprecipitation, ubiquitination and blotting
Cells were lysed in RIPA buffer for ubiquitination and lipid strip assays or in co-immunoprecipitation buffer, and immunoprecipitations and immunoblotting were conducted as previously described. 29 Rho/Rac pulldowns Active Rac and Rho were measured as described. 49 Briefly, cleared GBM cell lysates were incubated with glutathione beads bound with GST-Rhotekin-RBD or GST-PAK-PBD. Beads were washed with GTPase wash buffer, resuspended in SDS-DTT lysis buffer and boiled supernatants immunoblotted.
Lipid strips
Cleared RIPA lysates from transfected HEK293T cells were incubated with anti-FLAG M2 affinity gel beads (Sigma) for 4 h at 4°C. Beads were washed in RIPA buffer five times, then PBS, and FLAG-Dvl1 was eluted with 100 μl FLAG-peptide (Sigma) solution (0.5 mg/ml peptide, PBS, protease and phosphatase inhibitors) for 30 min at 4°C. Beads were removed and a fraction of eluate was saved. Purified protein was re-suspended in 2 ml blocking buffer (1x PBS-T (0.1% Tween-20), 3% bovine serum albumin) with
